About DBV Technologies
DBV Technologies: Revolutionizing Food Allergy Treatments
DBV Technologies is a global clinical stage biopharmaceutical company that is dedicated to developing safe and effective treatments for food allergies. The company was founded in 2002 by Dr. Pierre-Henri Benhamou, who recognized the need for a better way to treat food allergies after his own son suffered from severe peanut allergy.
Since then, DBV Technologies has been at the forefront of research and development in the field of food allergy treatments. The company's mission is to improve the lives of millions of people around the world who suffer from food allergies by providing them with safe and effective treatment options.
DBV Technologies' flagship product is Viaskin, a non-invasive patch that delivers small amounts of allergens through the skin. Viaskin has been shown to be safe and effective in clinical trials for peanut allergy, milk allergy, and egg allergy.
The Viaskin patch works by desensitizing patients to their allergens over time. By gradually exposing patients to small amounts of their allergen through the skin, Viaskin helps their immune system build up tolerance so that they can safely consume foods that would otherwise trigger an allergic reaction.
Viaskin has several advantages over other forms of immunotherapy for food allergies. Unlike oral immunotherapy (OIT), which involves consuming increasing amounts of allergen under medical supervision, Viaskin does not require patients to ingest any allergen. This makes it safer and more convenient for patients who may be at risk for severe reactions during OIT.
Viaskin also has fewer side effects than other forms of immunotherapy because it delivers allergens directly through the skin rather than through the digestive system. This means that there is less risk of gastrointestinal symptoms such as nausea or vomiting.
In addition to its work on Viaskin, DBV Technologies is also exploring other innovative approaches to treating food allergies. The company's pipeline includes several other products in various stages of development, including a vaccine for peanut allergy and a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disease caused by an allergic reaction in the esophagus.
DBV Technologies' commitment to improving patient outcomes extends beyond its research efforts. The company also works closely with patient advocacy groups such as Food Allergy Research & Education (FARE) and Allergy & Asthma Network (AAN) to raise awareness about food allergies and advocate for better access to care.
Overall, DBV Technologies is leading the way in developing safe and effective treatments for food allergies. With its innovative approach using non-invasive patches like Viaskin along with ongoing research into new therapies like vaccines and EoE treatments - this biopharmaceutical company continues making strides towards revolutionizing how we treat these life-threatening conditions today!
dbv-technologies.com
